You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

61 Results
Guidelines and Advice
Status: Archived
ID: HBOT
Jul 2013
Guidelines and Advice
Status: Archived
ID: 3-8-1
Apr 2013
Guidelines and Advice
Status: Archived
ID: 4-10
Aug 2013
Guidelines and Advice
Status: Archived
ID: 5-1
Apr 2013
Guidelines and Advice
Status: Archived
ID: 6-15
Dec 2013
Guidelines and Advice
Status: Archived
ID: 9-2
Nov 2013
Guidelines and Advice
Status: Archived
ID: 6-17
Nov 2013
Guidelines and Advice
Status: Archived
ID: 6-2
Version: 2
Aug 2013
Guidelines and Advice
Status: Archived
ID: 9-7
Mar 2013
Guidelines and Advice
Status: Archived
ID: 12-8
Version: 2
Jun 2013
Statistical Reports
Mar 2013
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niraparib / abiraterone,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025

Pages